In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

The study compared camizestrant in combination with CDK4/6 inhibitor drugs – such as Pfizer's Ibrance (palbociclib), Novartis' Kisqali (ribociclib), or Eli Lilly's Verzenios (abemaciclib) – to ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone ...

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...

Panelists emphasize that effective use of menin inhibitors for KMT2A-rearranged acute myeloid leukemia (AML) requires dispelling common misconceptions about oral targeted therapy, ensuring close ...